Brief: Sprint Bioscience Completes Strategic Evaluation Of STK25 Program
16/04/2026 07:04
April 16 (Reuters) - Sprint Bioscience AB SPRINT.ST: COMPLETES STRATEGIC EVALUATION OF STK25 PROGRAM WITH EDDC EVALUATION DOES NOT SUPPORT PROCEEDING TO ANOTHER INFLAMMATORY INDICATION Source text: ID:nMFNj1DbZ Further company coverage: SPRINT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln